Positive Phase 3 ARDS data and recent insider buying fuel today's 24% surge in Edesa Biotech.
Edesa Biotech's shares jumped sharply on March 20, 2026, trading around 24% higher intraday with elevated volume, building on momentum from earlier in the month. The primary driver traces to strengthened results from the Phase 3 trial of paridiprubart (EB05) in acute respiratory distress syndrome (ARDS), which demonstrated statistically significant reductions in 28-day mortality (24% vs. 33% on placebo plus standard of care in the full 278-patient population, a 27% relative risk reduction with p<0.001). Additional exploratory data showed even stronger benefits in non-ventilated patients. These findings, initially reported in late February and further detailed in early March, have been highlighted in analyst coverage and selected for an oral presentation at the American Thoracic Society 2026 conference in May. Recent insider purchases by the CEO and others in early March (totaling over $180,000 across several transactions) reinforced confidence. High retail interest and short interest amplification contributed to the volatility, though no brand-new announcement appears tied directly to March 20 trading.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.